In reply

Wong, Anselm; Landersdorfer, Cornelia B.; Graudins, Andis

doi:10.1007/s00228-017-2380-6

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For repeated supratherapeutic ingestion, Australian medical guidelines allow the discontinuation of N-acetylcysteine after 8 hours if ALT is normal or stable and APAP serum levels are low at this time [38]. Since pharmacokinetic models suggest the presence of N-acetylcysteine for several hours post-administration [39], it may confer protective effects even after patients are released [23]. In order to investigate the validity of these guidelines, a retrospective study was conducted with 91 cases, 39 of which received the abbreviated regimen.…”

Section: Improvements To Existingmentioning

confidence: 99%

Medicinal Thiols: Current Status and New Perspectives

Pfaff

Beltz

King

et al. 2020

MRMC

View full text Add to dashboard Cite

The thiol (-SH) functional group is found in a number of drug compounds and confers a unique combination of useful properties. Thiol-containing drugs can reduce radicals and other toxic electrophiles, restore cellular thiol pools, and form stable complexes with heavy metals such as lead, arsenic, and copper. Thus, thiols can treat a variety of conditions by serving as radical scavengers, GSH prodrugs, or metal chelators. Many of the compounds discussed here have been in use for decades, yet continued exploration of their properties has yielded new understanding in recent years, which can be used to optimize their clinical application and provide insights into the development of new treatments. The purpose of this narrative review is to highlight the biochemistry of currently used thiol drugs within the context of developments reported in the last five years. More specifically, this review focuses on thiol drugs that represent the standard of care for their associated conditions, including N-acetylcysteine, 2,3-meso-dimercaptosuccinic acid, British anti-Lewisite, D-penicillamine, amifostine, and others. Reports of novel dosing regimens, delivery strategies, and clinical applications for these compounds were examined with an eye toward emerging approaches to address a wide range of medical conditions in the future.

show abstract

Section: Improvements To Existingmentioning

confidence: 99%